Efficacy and Safety of Fixed-dose Combination of Etoricoxib/Tramadol vs Acetaminophen/Tramadol for Acute Low Back Pain

Last updated: April 12, 2022
Sponsor: Laboratorios Silanes S.A. de C.V.
Overall Status: Completed

Phase

3

Condition

Chronic Pain

Treatment

N/A

Clinical Study ID

NCT04968158
SIL-30138-III-21(1)
  • Ages 18-60
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

Phase IIIb, longitudinal, multicenter, randomized, open-label clinical trial to evaluate the efficacy and safety of the fixed-dose combination of etoricoxib 90 mg and tramadol 50 mg compared with fixed-dose therapy of acetaminophen 325 mg and tramadol 37.5 mg for the management of acute low back pain.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Any sex.
  • That the subject agree to participate in the study and give informed consent inwriting.
  • Age> 18 years and ≤ 60 years of age at the beginning of the study.
  • Diagnosis of acute low back pain as a first-time episode or after another episode,maximum 6 months before and lasting no more than 6 weeks.
  • Patient with low back pain reported as moderate to severe intensity (VAS> 4 cm).
  • Women of childbearing age who have an acceptable contraceptive method (eg barrier,oral hormonal, injectable, subdermal).

Exclusion

Exclusion Criteria:

  • Patients in whom the study drug is contraindicated for medical reasons.
  • Patients with an allergy or hypersensitivity to the active principle, study drugs,related products or excipients.
  • Positive pregnancy test, women who are pregnant, breastfeeding or planning a pregnancywhile conducting the study.
  • A significant history of gastrointestinal disorders (for example: Gastric ulcer,Crohn's disease, Ulcerative Colitis, etc.).
  • Previous treatment with opioids and / or NSAIDs (Non-Steroidal Anti-InflammatoryDrugs) reported in the medical history in the last 72 hours at study entry.
  • Patients with a history of alcohol or drug abuse in the last year according to DSM-V (Diagnostic and Statistical Manual of Mental Disorders).
  • Patients who are receiving monoamine oxidase inhibitors (MAOIs) or who have receivedthem within the past 2 weeks.
  • Patients with a history of established ischemic heart disease, peripheral arterialdisease and / or cerebrovascular disease (including patients who have recentlyundergone coronary artery bypass grafting or angioplasty).
  • Patients with status epileptic seizure disorders and grand mal seizures.
  • Patients with a history of severe acute or chronic liver failure.
  • Patients with a history of moderate to severe renal failure.
  • Patient with a history of chronic pain (eg, fibromyalgia, Paget's disease, bone paininduced by metastatic cancer).
  • Low back pain due to major trauma (eg vertebral fracture, post-traumaticspondylolisthesis), or due to a visceral disorder (eg dysmenorrhea, endometriosis).
  • At medical criteria, a disease that affects the prognosis and prevents outpatientmanagement, for example, but not restricted to: intestinal obstruction, paralyticileus, end-stage cancer, kidney, heart, respiratory or liver failure or mental illnessor with surgical procedures or scheduled hospitals.
  • History / presence of any disease or condition that, in the Investigator's opinion,could pose a risk to the patient or confuse the efficacy and safety of the studyresults. ----Patients with symptoms suggesting an active COVID-19 infection (i.e.,fever, cough, dyspnea) and / or contact in the past 14 days with a suspected orpositive COVID-19 patient.
  • Oncological patients (except basal cell skin cancer) or with serious diseases that, inthe opinion of the investigator, have a serious prognosis or a life expectancy of lessthan 1 year, as well as mental illnesses.
  • The patient is participating in another clinical study involving an investigationaltreatment or participated in one in the previous 4 weeks.
  • Patients whose participation in the study may be influenced (employment relationshipwith the research center or sponsor, inmates, etc.).

Study Design

Total Participants: 124
Study Start date:
November 29, 2021
Estimated Completion Date:
April 10, 2022

Study Description

Patients with back pain from the level of the lowest rib to the gluteal crease, with or without radiation to the legs, as a first-time episode or after another at least 6 months before and lasting no more than 6 weeks, that in the opinion of the doctor requires treatment with the combination of an anti-inflammatory and an analgesic. Study to evaluate the efficacy and safety of the fixed-dose combination of etoricoxib 90 mg and tramadol 50 mg compared with the fixed-dose therapy of acetaminophen 325 mg and tramadol 37.5 mg for the management of acute low back pain. Evaluate and compare the average change in pain reported through the VAS at 3, 5 and 7 days with respect to its baseline measurement by treatment group. An exploratory analysis of the data will be carried out to identify aberrant, outliers, or missing values. To present the numerical variables, the measures of central tendency and dispersion appropriate to the distribution of the data will be used and the categorical variables will be expressed as frequency and percentage.

Connect with a study center

  • Laboratorio Silanes, S.A. de C.V.

    Mexico City, 11000
    Mexico

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.